The Enterprise Value as of November 2024 (TTM) for Entrada Therapeutics, Inc. (TRDA) is 540.23M

According to Entrada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 540.23M. This represents a change of 15.26% compared to the average of 468.69M of the last 4 quarters.

Entrada Therapeutics, Inc. (TRDA) Historical Enterprise Value (quarterly & annually)

How has TRDA Enterprise Value performed in the past?

The mean historical Enterprise Value of Entrada Therapeutics, Inc. over the last ten years is 517.53M. The current 540.23M Enterprise Value has changed 10.34% with respect to the historical average. Over the past ten years (40 quarters), TRDA's Enterprise Value was at its highest in in the September 2021 quarter at 555.91M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Entrada Therapeutics, Inc. (TRDA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Entrada Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Entrada Therapeutics, Inc. (TRDA) Average Enterprise Value

How has TRDA Enterprise Value performed in the past?

The current Enterprise Value of Entrada Therapeutics, Inc. (TRDA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Entrada Therapeutics, Inc. (TRDA) Enterprise Value vs. Peers

How is TRDA’s Enterprise Value compared to its peers?

Entrada Therapeutics, Inc.’s Enterprise Value is greater than Molecular Partners AG (57.47M), greater than PMV Pharmaceuticals, Inc. (48.13M), greater than Monte Rosa Therapeutics, Inc. (478.04M), greater than Vigil Neuroscience, Inc. (129.53M), greater than Third Harmonic Bio, Inc. (245.75M), less than Cullinan Oncology, Inc. (810.70M), less than Edgewise Therapeutics, Inc. (3.19B), greater than Rallybio Corporation (25.93M), less than Crinetics Pharmaceuticals, Inc. (4.87B), less than Centessa Pharmaceuticals plc (1.76B), less than Disc Medicine, Inc. (1.23B), greater than Larimar Therapeutics, Inc. (453.31M), greater than PepGen Inc. (174.61M), less than Tyra Biosciences, Inc. (772.84M), less than Pharvaris N.V. (844.45M), less than Eliem Therapeutics, Inc. (0), greater than Genenta Science S.p.A. (119.64M), greater than Opthea Limited (85.42M), less than Pardes Biosciences, Inc. (656.58M), greater than null (34.92M),

Build a custom stock screener for Entrada Therapeutics, Inc. (TRDA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Entrada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Entrada Therapeutics, Inc. (TRDA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Entrada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.